{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:06:39Z","timestamp":1784289999413,"version":"3.55.0"},"reference-count":3,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaad.2026.03.114","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:45:10Z","timestamp":1777045510000},"page":"e223-e225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to \u201cElevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u201d"],"prefix":"10.1016","volume":"95","author":[{"given":"Harrison P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Ted","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Sobell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2026.03.114_bib1","first-page":"293","article-title":"Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: a population-based analysis using TriNetX","volume":"94","author":"Woodie","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.03.114_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2025.11.033","volume":"94","author":"Blauvelt","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.03.114_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222602517X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222602517X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:38:17Z","timestamp":1784288297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222602517X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":3,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S019096222602517X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.114","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to \u201cElevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.03.114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}